Evidence map›Paper›PMID 40912259›Full record

SynthesisThe lancet. HIV2025

HIV-related mortality time trends among children and young adolescents on antiretroviral therapy by age, treatment duration, and region: a systematic review and meta-regression analysis.

Jiawei He, Edmond Brewer, Amanda Novotney, Austin Carter, Hilary Paul, Magdalene K Walters, Kemal Sherefa Oumer, Reshma Kassanjee, Joycelyn Dame, Sophie Desmonde and 16 more

Erratum issuedAbstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in The lancet. HIV, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Jiawei HeInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Edmond BrewerInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Amanda NovotneyInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Austin CarterInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Hilary PaulInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Magdalene K WaltersMRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
Kemal Sherefa OumerInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Reshma KassanjeeCentre for Integrated Data and Epidemiological Research, School of Public Health, University of Cape Town, Cape Town, South Africa.
Joycelyn DameDepartment of Child Health, University of Ghana Medical School and Korle Bu Teaching Hospital, Accra, Ghana.
Sophie DesmondeInstitut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Epidémiologie et de Recherche en Santé des Populations (CERPOP), Université de Toulouse, Toulouse, France.
Brian EleyDepartment of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
Azar KariminiaThe Kirby Institute, UNSW Sydney, NSW, Australia.
Denis NashInstitute for Implementation Science in Population Health and Department of Epidemiology and Biostatistics, CUNY Graduate School of Public Health, City University of New York (CUNY), New York, NY, USA.
Peter F RebeiroVanderbilt University Medical Center, Nashville, TN, USA.
Vanessa RouzierLes Centres GHESKIO, Port-au-Prince, Haiti.
Tavitiya SudjaritrukDivision of Infectious Diseases, Department of Pediatrics, Faculty of Medicine and Clinical and Molecular Epidemiology of Emerging and Re-Emerging Infectious Diseases Research Cluster, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Kara Wools-KaloustianDepartment of Medicine, School of Medicine, Indiana University, Bloomington, IN, USA.
Constantin T YiannoutsosGraduate School of Public Health and Health Policy, City University of New York, New York, NY, USA.
Marcel YotebiengDivision of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, New York, NY, USA.
Reed J D SorensenInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Christopher J L MurrayInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Simon I HayInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Aleksandr AravkinInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Abraham FlaxmanInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Peng ZhengInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Hmwe H KyuInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA. Electronic address: hmwekyu@uw.edu.

Funding

East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional ConsortiumU01AI069911 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI AGGREY SEMWENDERO SEMEERE, Kara Kay Wools-Kaloustian · 2006 to 2026
$57.7M
Observational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9M
The Asia-Pacific HIV Research CollaborationU01AI069907 · NIAID · FOUNDATION FOR AIDS RESEARCH · PI ANNETTE H SOHN · 2006 to 2026
$44.8M
CCASAnet: Caribbean, Central and South America NetworkU01AI069923 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Pedro Enrique Cahn, Jessica L Castilho · 2006 to 2026
$41.6M
"Enhancing Cancer Research in Central Africa IeDEA"U01AI096299 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Denis Nash, Marcel Yotebieng · 2011 to 2026
$35.8M
WADA (West Africa Database on Antiretroviral Therapy) CollaborationU01AI069919 · NIAID · UNIVERSITY OF BORDEAUX II · PI Didier Koumavi Ekouevi, Antoine Jaquet · 2006 to 2026
$29.9M
Quantification of HIV burden and the biomedical, structural, and behavioral factors influencing HIV/AIDS among children and young adolescentsR01AI152721 · NIAID · UNIVERSITY OF WASHINGTON · PI KYU, HMWE HMWE · 2021 to 2025
$3.6M
NIAID NIH HHS R01 AI152721NIAID NIH HHS U01 AI069907NIAID NIH HHS U01 AI069911NIAID NIH HHS U01 AI069919NIAID NIH HHS U01 AI069923NIAID NIH HHS U01 AI069924NIAID NIH HHS U01 AI096299
6 · The paper itself

Abstract

backgroundPast cohort studies have examined mortality among children and young adolescents (aged 0-14 years) who have received antiretroviral therapy (ART), but no systematic reviews have been undertaken to synthesise these findings. Our study aims to provide the most comprehensive global estimates of paediatric mortality among children and adolescents receiving ART.

methodsFor this systematic review and meta-regression analysis, we searched PubMed and Embase from Jan 1, 1990 to July 31, 2024 for studies reporting mortality among children and young adolescents living with HIV who were on ART. We employed the meta-regression with Bayesian priors, regularisation, and trimming tool, developed for the Global Burden of Disease study 2019, for meta-regression analysis to estimate on-ART mortality by region, CD4 cell count or percentage, age, sex, and treatment duration. We assessed the robustness of our results by doing a sensitivity analysis, restricting it to studies of good quality using the quality assessment tool adapted from the Newcastle-Ottawa Scale and the National Heart, Lung, and Blood Institute. This study has been registered with PROSPERO (CRD42022382702).

findingsOur literature search identified 7588 records, of which 5853 were determined relevant for title and abstract review. Following screening, 1068 records were selected for full-text assessment. We included 84 studies in our systematic review, of which 66 were included in the meta-regression analysis. Our analysis indicated that HIV-related mortality for all children and young adolescents (aged 0-14 years) decreased over time, between 2000 and 2020 globally, after adjusting for region, baseline CD4 cell count, age, treatment duration, and sex. Additionally, HIV-related mortality decreased with increasing CD4 cell count at ART initiation and longer treatment duration. There have been considerable geographical variations in the risk of mortality. Among the high-mortality group in 2020 (ART duration <6 months, age <1 year, male, and the lowest CD4 cell counts), HIV-related mortality across regions ranged from 11·7 deaths (95% CI 8·3-15·4) per 100 person-years in eastern Sub-Saharan Africa to 72·0 deaths (47·1-98·1) per 100 person-years in Asia-Pacific. Among the low-mortality group in 2020 (ART duration ≥1 year, age 5-9 years, female, and the highest CD4 cell counts), HIV-related mortality ranged from 0·09 deaths (0·07-0·10) per 100 person-years in eastern Sub-Saharan Africa to 0·20 deaths (0·03-0·80) per 100 person-years in Latin America and the Caribbean.

interpretationA comprehensive approach to paediatric HIV care is essential to improving outcomes for children and young adolescents living with HIV. Clinically, this approach includes strengthening the prevention of vertical transmission, ensuring early diagnosis in infants, and initiating treatment promptly-ideally at higher CD4 cell counts. From a policy perspective, health systems need to address disparities in treatment access and outcomes across regions, age groups, and sex. Efforts should also prioritise minimising treatment dropout and expanding access to high-quality HIV services. These strategies could collectively support global goals to reduce the burden of paediatric HIV.

fundingThe National Institute of Allergy and Infectious Diseases and the National Institutes of Health.

Indexed as

Anti-HIV AgentsHIV InfectionsAdolescentAge FactorsCD4 Lymphocyte CountChildChild, PreschoolFemaleHumansInfantInfant, NewbornMaleRegression AnalysisAnti-HIV Agents

Identifiers

PMID40912259
PMCPMC12774562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.